Form
SCHEDULE 13G/A
Passive or exempt beneficial ownership filing.
Arie Belldegrun - 31 Dec 2025 SCHEDULE 13G/A Report for Allogene Therapeutics, Inc. Common Stock (ALLO)
- Filing manager
- Arie Belldegrun
- Reporting owner
- Arie Belldegrun, M.D.
- Beneficially owned shares
- 13,248,170 shares
- Large-stake signal
-
Ownership
5.8%Beneficial ownership of this reported class.
Shares
13,248,170 sharesShares beneficially owned as disclosed.
Event date
31 Dec 2025Date tied to the ownership event or amendment.
Accepted by SEC
17 Feb 2026EDGAR acceptance date.
How to read this large-stake filing
- Schedule 13D/G filings focus on beneficial ownership stakes, not a full portfolio.
- Compare this filing with the holder history and issuer page before treating the percentage as a current position.
- Use amendments to understand whether the disclosed stake increased, decreased, or changed reporting status.
- Class ownership
- 5.8%
- Symbol
- ALLO
- Shares outstanding
- 228,416,724 shares
- SEC form
- SCHEDULE 13G/A
- Accepted by SEC
- 17 Feb 2026, 17:34:06 UTC
- Event date
- 31 Dec 2025
- Prior SEC filing
- 13 Nov 2025
- Next SEC filing
- 13 May 2026
- Source filing
- View source filing
Ownership signal
CIK-linked ownership evidence from parsed SEC filings.
2 signals
Subject security
Names, identifiers, and filing context for this profile.
2 source fields
Source evidence
Original filing metadata and source links for verification.
6 source fields
Key filing fact
Arie Belldegrun disclosed 5.8% ownership in Allogene Therapeutics, Inc. Common Stock (ALLO) on 31 Dec 2025.
Key facts
- Arie Belldegrun filed SCHEDULE 13G/A for Allogene Therapeutics, Inc. Common Stock (ALLO).
- Disclosed ownership: 5.8%.
- Date of event: 31 Dec 2025.
Change
- Previous schedule filing date: 13 Nov 2025.
- Current filing was accepted on 17 Feb 2026, 17:34.
Research use
- This page turns one Schedule 13D/G filing into a quick large-stake read before the raw reporting-person rows.
- Use the linked SEC filing as the source of truth for ownership percentages, shares, and reporting-party details.
Evidence
Backed by Schedule 13D/13G
View source filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting persons
Disclosed reporting parties (6)
Names, ownership percentages, voting power, signatures, titles, and CIKs as disclosed in this Schedule 13D/G filing.
| Name | Ownership | Shares owned | Sole voting power | Shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Arie Belldegrun, M.D. | 5.8% | 13,248,170 | 4,475,883 | 8,772,287 | /s/ Arie Belldegrun | Arie Belldegrun, M.D. | |
| Bellco Legacy LLC | 0.2% | 539,867 | 0 | 539,867 | /s/ Arie Belldegrun | By Arie Belldegrun, M.D., Manager | |
| Bellco Legacy IV LLC | 2.1% | 4,710,120 | 0 | 4,710,120 | /s/ Arie Belldegrun | By Arie Belldegrun, M.D., Manager | |
| Vida Ventures LLC | 0.8% | 1,798,163 | 0 | 1,798,163 | /s/ Arie Belldegrun | By VV Manager LLC, its Manager, By Arie Belldegrun, M.D., Senior Managing Director | |
| Vida Ventures III, L.P. | 0.8% | 1,720,172 | 0 | 1,720,172 | /s/ Arie Belldegrun | By Vida Ventures GP III, LLC, its Manager, By Arie Belldegrun, M.D., Senior Managing Director | |
| Vida Ventures III-A, L.P. | 0% | 3,965 | 0 | 3,965 | /s/ Arie Belldegrun | By Vida Ventures GP III, LLC, its Manager, By Arie Belldegrun, M.D., Senior Managing Director, |
CIK / CUSIP context first